Nomad Power Solutions Inc. (NMAD)
NMAD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | NMAD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001335105 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
No annual revenue filed since the period ending 2015-12-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result of the foregoing, management has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern for a period of at least 12 months beyond the date these condensed consolidated financial statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $12.7M cash; operating cash flow -$1.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 16,101,068 (2026-08-10); 4,561,363 a year earlier; 2,249,290 three years earlier. | Cover page 2026-08-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE/A filed | 25-NSE/A 2025-11-28 |
| Auditor | Weinberg & Company, P.A., Los Angeles, California, United States | PCAOB Form AP 2026-04-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$2.3M | -$1.6M | $12.7M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$2.0M | -$1.8M | $3.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$2.6M | -$1.1M | $5.1M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$2.0M | -$927K | $2.9M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$776K | -$487K | $887K | No debt tags | Needs four quarters | 10-Q 2025-08-07 |
| Q1 2025 2025-03-31 | Not filed | -$710K | -$568K | $1.4M | No debt tags | Needs four quarters | 10-Q 2025-05-12 |
| Q4 2024 2024-12-31 | Not filed | -$618K | -$599K | $1.0M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$986K | -$958K | $1.6M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-04 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-07-27 |
Source: SEC EDGAR submissions feed, 534 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -34.7% |
| 1 month | -45.1% |
| 3 months | -42.0% |
| Year to date | -40.2% |
| 1 year | -45.3% |
| From 52-week high | -70.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TLPH | Talphera Inc. | $0.8609 | -4.98% | $44.7M |
| MIST | Milestone Pharmaceuticals Inc. Common Shares | $0.3650 | -29.81% | $45.4M |
| HYFT | MindWalk Holdings Corp. | $0.9378 | -8.95% | $44.6M |
| ONCY | Oncolytics Biotech Inc. | $0.3399 | -8.14% | $44.6M |
| RNXT | RenovoRx Inc. | $0.9549 | -8.18% | $46.1M |
| ANVS | Annovis Bio Inc. | $0.7500 | -19.02% | $46.5M |
| ATNM | Actinium Pharmaceuticals Inc. (Delaware) | $1.49 | -9.15% | $46.8M |
| PLRX | Pliant Therapeutics Inc. | $0.6932 | -0.55% | $43.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier